



# News Release

## **Takeda Announces Appointment of Christophe Weber as Chief Executive Officer**

**Osaka, Japan, March 4, 2015** -- Takeda Pharmaceutical Company Limited today announced that its Board of Directors decided to promote Christophe Weber, Representative Director, President & Chief Operating Officer (COO), to Representative Director, President & Chief Executive Officer (CEO), effective April 1, 2015. Yasuchika Hasegawa, Representative Director, Chairman of the Board & CEO, will assume the position of Representative Director, Chairman of the Board.

The appointment is the result of a transparent and objective decision-making process endorsed by the Nomination Committee, which has been established as an advisory body to the Board of Directors and whose chairperson is an Outside Director. It has been also decided that the position of COO will no longer exist effective April 1, 2015.

Christophe Weber, the Representative Director, President & COO, said “First, I would like to thank Yasuchika Hasegawa and the Board of Directors for their trust. I am honored and thrilled with the role of CEO and determined to fulfill my duties. I will devote all my energy to leading the new Takeda organization from April 1, 2015, and continue to make contributions to patients and healthcare professionals, to engage and motivate our employees, while responding to the expectations of investors and shareholders.”

Yasuchika Hasegawa, the Representative Director, Chairman of the Board & CEO, said “Since he became COO of the Company last April, I have been supporting Christophe and at the same time carefully observing his performance as a CEO successor. I have concluded that he is ready to assume Takeda’s CEO role, and therefore I have decided to appoint him CEO when the new organizational structure takes effect on April 1, 2015. Under “Takeda-ism (Integrity: Fairness, Honesty, and Perseverance),” I am confident that Christophe will blaze a new trail in our efforts to help people realize better health and a brighter future.”

**1. Name and title of the Representative Directors**

<b>New position</b>	<b>Previous position</b>	<b>Name</b>
Representative Director, Chairman of the Board	Representative Director, Chairman of the Board & Chief Executive Officer (CEO)	Yasuchika Hasegawa
Representative Director, President & Chief Executive Officer (CEO)	Representative Director, President & Chief Operating Officer (COO)	Christophe Weber

**2. Date of birth, number of shares of the Company owned and profile of the Representative Directors**

Yasuchika Hasegawa

Date of Birth: June 19, 1946

Number of Shares of the Company Owned: 107,700

Profile:

April 1970	Joined the Company
October 1998	Corporate Officer and Senior Vice President, Pharmaceutical International Division of the Company
June 1999	Director of the Company
June 2001	Senior Vice President, Corporate Planning Department of the Company
April 2002	Senior Vice President, Corporate Strategy & Planning Department of the Company
June 2003	President and Representative Director of the Company
April 2011	Chairman, KEIZAI DOYUKAI (Japan Association of Corporate Executives) (to present)
April 2014	Chief Executive Officer of the Company (to present)
June 2014	Representative Director, Chairman of the Board & CEO of the Company (to present)

Christophe Weber

Date of Birth: November 14, 1966

Number of Shares of the Company Owned: 0

Profile: July 2003 Chairman & CEO, GlaxoSmithKline France  
May 2008 Senior Vice President & Regional Director, Asia Pacific,  
GlaxoSmithKline  
January 2011 President & General Manager Designate, GlaxoSmithKline Vaccines  
April 2012 President & General Manager, GlaxoSmithKline Vaccines  
April 2012 CEO, GlaxoSmithKline Biologicals  
April 2012 Member of GlaxoSmithKline Corporate Executive Team  
April 2014 Chief Operating Officer of the Company (to present)  
April 2014 Corporate Officer of the Company  
June 2014 President and Representative Director of the Company (to present)

**3. Scheduled date of appointment**

April 1, 2015

###